REG - Hutchmed China Ltd - Notice of Extraordinary General Meeting

HUTCHMED (China)Announcement

13/03/2025 09:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM4299Aa&default-theme=true

RNS Number : 4299A  Hutchmed (China) Limited  13 March 2025

 

 

Notice of Extraordinary General Meeting

 

Hong Kong, Shanghai, & Florham Park, NJ - Thursday, March 13, 2025:
HUTCHMED (China) Limited ("HUTCHMED (https://www.hutch-med.com/) " or the
"Company") (Nasdaq/AIM: HCM; HKEX: 13) today announces that its Circular
(including Notice of Extraordinary General Meeting) and the Form of Proxy
("EGM Materials"), will be posted on March 14, 2025 to those shareholders who
have elected to receive the EGM Materials in printed form. The documents can
also be accessed from the HUTCHMED website (www.hutch-med.com
(https://www.hutch-med.com/) ).

 

The 2025 Extraordinary General Meeting ("EGM") will be an electronic/hybrid
meeting to be held at 47th Floor, Cheung Kong Center, 2 Queen's Road Central,
Hong Kong on Monday, March 31, 2025 at 3:00 pm Hong Kong Time (8:00 am London
Time), with online access through an online platform as detailed in the EGM
Materials.

 

The EGM is being convened for the purposes of approving the Company's proposed
disposal of its 45% equity interest in Shanghai Hutchison Pharmaceuticals
Limited (as first announced January 1, 2025 and further announced on March 2,
2025). Shareholders are encouraged to read the EGM Materials in full.

 

 

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage,
biopharmaceutical company. It is committed to the discovery, global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Since inception,
HUTCHMED has focused on bringing drug candidates from in-house discovery to
patients around the world, with its first three medicines marketed in China,
the first of which is also approved in the US, Europe and Japan. For more
information, please visit: www.hutch‑med.com (https://www.hutch-med.com/) or
follow us on LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

CONTACTS
 Investor Enquiries                                   +852 2121 8200 / ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 FTI Consulting -                                     +44 20 3727 1030 / HUTCHMED@fticonsulting.com
                                                      (mailto:HUTCHMED@fticonsulting.com)
    Ben Atwell / Alex Shaw                               +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile)
 Brunswick - Zhou Yi                                  +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                      (mailto:HUTCHMED@brunswickgroup.com)

 Panmure Liberum                                      Nominated Advisor and Joint Broker
 Atholl Tweedie / Freddy Crossley / Rupert Dearden    +44 20 7886 2500

 HSBC                                                 Joint Broker
 Simon Alexander / Alina Vaskina / Arnav Kapoor       +44 20 7991 8888

 Cavendish                                            Joint Broker
 Geoff Nash / Nigel Birks                             +44 20 7220 0500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOGFZGMFKZFGKZM